1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014

Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Streptococcus Pneumoniae Infection - Pipeline Review, H1 2014’, provides an overview of the Streptococcus Pneumoniae Infection’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Streptococcus Pneumoniae Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Streptococcus Pneumoniae Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Streptococcus Pneumoniae Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Streptococcus Pneumoniae Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Streptococcus Pneumoniae Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Streptococcus Pneumoniae Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Streptococcus Pneumoniae (Pneumococcus) Infections Overview 10
Therapeutics Development 11
Pipeline Products for Streptococcus Pneumoniae (Pneumococcus) Infections - Overview 11
Pipeline Products for Streptococcus Pneumoniae (Pneumococcus) Infections - Comparative Analysis 12
Streptococcus Pneumoniae (Pneumococcus) Infections - Therapeutics under Development by Companies 13
Streptococcus Pneumoniae (Pneumococcus) Infections - Therapeutics under Investigation by Universities/Institutes 16
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Streptococcus Pneumoniae (Pneumococcus) Infections - Products under Development by Companies 21
Streptococcus Pneumoniae (Pneumococcus) Infections - Products under Investigation by Universities/Institutes 23
Streptococcus Pneumoniae (Pneumococcus) Infections - Companies Involved in Therapeutics Development 24
GlaxoSmithKline plc 24
Merck and Co., Inc. 25
Dainippon Sumitomo Pharma Co., Ltd. 26
Liquidia Technologies, Inc. 27
SK Chemicals Co., Ltd. 28
Panacea Biotec Limited 29
Eurocine Vaccines AB 30
FluGen, Inc. 31
Mucosis B.V. 32
GlycoVaxyn AG 33
Nabriva Therapeutics AG 34
Sinovac Biotech Ltd. 35
Genocea Biosciences, Inc. 36
Serum Institute of India Limited 37
Wellstat Vaccines, LLC 38
Beijing Minhai Biotechnology Co., Ltd 39
Furiex Pharmaceuticals, Inc. 40
ContraFect Corporation 41
Chongqing Zhifei Biological Products Co., Ltd. 42
Sanofi Pasteur SA 43
Valneva SE 44
Abera Bioscience AB 45
Streptococcus Pneumoniae (Pneumococcus) Infections - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Target 47
Assessment by Mechanism of Action 49
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 56
Pneumococcal Polysaccharide Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
NBP-606 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
V-114 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
GSK-2189242A - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
avarofloxacin hydrochloride - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
S. Pneumoniae Paediatric Next Generation Vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
Conjugated Pneumococcal Vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
GSK-2830929A - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Inactivated Whole Cell Vaccine for Streptococcus Pneumoniae - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
Nucovac - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
Streptococcus Pneumoniae Meningitis Vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
GEN-004 - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
PlyD-1 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
13-valent Pneumococcal Conjugate Vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
SIILPCV-10 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
Pneumococcal Conjugate Vaccine - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
Pneumococcal Polysaccharides Vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
BC-3781 - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
Pneumococcus Antibodies - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
PneuGEM - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
Nasal Pneumococcal Vaccine - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
Pneumococcal Vaccine - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
Pneumococcal Vaccine - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
SM-295291 - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
SM-369926 - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
Vi-PspA Vaccine - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
Pneumococcal Vaccine - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
Multivalent Vaccine For Pneumococcal Disease - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
15-Valent Pneumococcal Conjugate Vaccine - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
Pneumococcal Vaccine - Drug Profile 89
Product Description 89
Mechanism of Action 89
RandD Progress 89
13-Valent Pneumococcal Conjugate Vaccine - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
Protein-Based Pneumococcal Vaccines - Drug Profile 91
Product Description 91
Mechanism of Action 91
RandD Progress 91
Drugs Targeting Gram Positive Bacteria - Drug Profile 92
Product Description 92
Mechanism of Action 92
RandD Progress 92
Pneumococcus Pneumolysoid Conjugate Vaccine - Drug Profile 93
Product Description 93
Mechanism of Action 93
RandD Progress 93
Pneumococcal Vaccine - Drug Profile 94
Product Description 94
Mechanism of Action 94
RandD Progress 94
Vaccine For Streptococcus pneumoniae - Drug Profile 95
Product Description 95
Mechanism of Action 95
RandD Progress 95
Pneumococcal Conjugate CRM Vaccine - Drug Profile 96
Product Description 96
Mechanism of Action 96
RandD Progress 96
Pneumo Proteic Vaccine - Drug Profile 97
Product Description 97
Mechanism of Action 97
RandD Progress 97
Streptococcus Pneumoniae (Pneumococcus) Infections - Recent Pipeline Updates 98
Streptococcus Pneumoniae (Pneumococcus) Infections - Dormant Projects 103
Streptococcus Pneumoniae (Pneumococcus) Infections - Discontinued Products 104
Streptococcus Pneumoniae (Pneumococcus) Infections - Product Development Milestones 105
Featured News and Press Releases 105
Mar 11, 2014: Liquidia Technologies Presents New Data on Next-Generation Pneumococcal Vaccines 105
Oct 25, 2013: Synflorix receives positive opinion from the CHMP in Europe for additional pneumonia indication 105
Sep 13, 2013: Nabriva Therapeutics Presented Data on Potency, Safety, Tolerability and Pharmacokinetics of Pleuromutilin Antibiotic BC-3781 106
Feb 25, 2013: Furiex Pharma Receives Qualified Infectious Disease Product And Fast Track Designations From FDA For Avarofloxacin 107
Nov 16, 2012: GlaxoSmithKline Announces Publication Of Positive Results Of Synflorix European Clinical Trial In Lancet In Preventing Invasive Pneumococcal Disease 108
Oct 17, 2012: Durata Therapeutics Announces Preclinical Data Supporting Clinical Development Of Dalbavancin For Treatment Of Pneumonia 109
Oct 09, 2012: GAVI Alliance To Introduce Synflorix Pneumococcal Vaccine In Pakistan 109
Sep 17, 2012: GSK Announces Submission For New Indication For Synflorix In Europe 110
Sep 05, 2012: Rib-X Pharma To Present Data On RX-04 Program At ICAAC 2012 111
Mar 27, 2012: Lorus Therapeutics Announces Positive Results From Small Molecule Antimicrobial Program 111
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 114
Disclaimer 114

List of Tables

Number of Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections, H1 2014 11
Number of Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Comparative Analysis by Unknown Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Development by Companies, H1 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2014 23
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by GlaxoSmithKline plc, H1 2014 24
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Merck and Co., Inc., H1 2014 25
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 26
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Liquidia Technologies, Inc., H1 2014 27
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by SK Chemicals Co., Ltd., H1 2014 28
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Panacea Biotec Limited, H1 2014 29
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Eurocine Vaccines AB, H1 2014 30
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by FluGen, Inc., H1 2014 31
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Mucosis B.V., H1 2014 32
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by GlycoVaxyn AG, H1 2014 33
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Nabriva Therapeutics AG, H1 2014 34
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Sinovac Biotech Ltd., H1 2014 35
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Genocea Biosciences, Inc., H1 2014 36
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Serum Institute of India Limited, H1 2014 37
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Wellstat Vaccines, LLC, H1 2014 38
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2014 39
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Furiex Pharmaceuticals, Inc., H1 2014 40
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by ContraFect Corporation, H1 2014 41
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2014 42
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Sanofi Pasteur SA, H1 2014 43
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Valneva SE, H1 2014 44
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Abera Bioscience AB, H1 2014 45
Assessment by Monotherapy Products, H1 2014 46
Number of Products by Stage and Target, H1 2014 48
Number of Products by Stage and Mechanism of Action, H1 2014 50
Number of Products by Stage and Route of Administration, H1 2014 52
Number of Products by Stage and Molecule Type, H1 2014 55
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics - Recent Pipeline Updates, H1 2014 98
Streptococcus Pneumoniae (Pneumococcus) Infections - Dormant Projects, H1 2014 103
Streptococcus Pneumoniae (Pneumococcus) Infections - Discontinued Products, H1 2014 104

List of Figures
Number of Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections, H1 2014 11
Number of Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Comparative Analysis by Unknown Stage Development, H1 2014 20
Assessment by Monotherapy Products, H1 2014 46
Number of Products by Top 10 Target, H1 2014 47
Number of Products by Stage and Top 10 Target, H1 2014 48
Number of Products by Top 10 Mechanism of Action, H1 2014 49
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 50
Number of Products by Top 10 Route of Administration, H1 2014 51
Number of Products by Stage and Top 10 Route of Administration, H1 2014 52
Number of Products by Top 10 Molecule Type, H1 2014 53
Number of Products by Stage and Top 10 Molecule Type, H1 2014 54

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.